Between Dec 19, 2024 and Jan 2, 2025, datasets can be submitted to DRUM but will not be processed until after the break. Staff will not be available to answer email during this period, and will not be able to provide DOIs until after Jan 2. If you are in need of a DOI during this period, consider Dryad or OpenICPSR. Submission responses to the UDC may also be delayed during this time.
 

Effect of N1-hexyl-N5-benzyl-biguanide mesylate (HBB) on Immediate Early Hormonal Signaling in MCF-7 Breast Cancer Cells

Loading...
Thumbnail Image

Persistent link to this item

Statistics
View Statistics

Journal Title

Journal ISSN

Volume Title

Title

Effect of N1-hexyl-N5-benzyl-biguanide mesylate (HBB) on Immediate Early Hormonal Signaling in MCF-7 Breast Cancer Cells

Published Date

2016

Publisher

Type

Presentation

Abstract

HBB is a chemical compound being tested as a possible drug to treat breast cancer in addition to other hormone therapies. However, its mechanism remains unclear. This set of experiments was done to understand how HBB treated cells react upon exposure to either estradiol or progesterone. By using western blot assays, it was determined that phosphorylated ERK levels increased in cells treated with HBB.

Description

Related to

Replaces

License

Series/Report Number

Funding information

This research was supported by the Undergraduate Research Opportunities Program (UROP).

Isbn identifier

Doi identifier

Previously Published Citation

Other identifiers

Suggested citation

Ji, Michelle, M. (2016). Effect of N1-hexyl-N5-benzyl-biguanide mesylate (HBB) on Immediate Early Hormonal Signaling in MCF-7 Breast Cancer Cells. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/181614.

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.